Aktuelle Therapiekonzepte bei malignen Kopf-Hals-Tumoren

Die Therapie von Kopf-Hals-Plattenepithelkarzinomen (HNSCC) richtet sich nach international anerkannten Leitlinien. Neben Chirurgie, Strahlentherapie und medikamentöser Tumortherapie gehören dazu auch molekularbiologische und immunologische Ansätze.

• Literatur

• 1 Barnes L. Eveson JW. Reichart P. et al. (Eds.) World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005
• 2 Union internationale contre le cancer (UICC). TNM Classification of Malignant Tumours. 8th edition. Dezember 2016
• 3 National Comprehensive Cancer Network. Clinical practice guidelinies, head and neck cancer. 2017 Version 1.
• 4 Sinha P. Kallogjeri D. Gay H. et al. High metastatic node number, not extracapsular spread or N-classification is a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer. Oral Oncology 2015; 51: 514-520
• 5 Wuthrick EJ. Zhang Q. Machtay M. et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 2015; 33: 156-164
• 6 Lassig AA. Joseph AM. Lindgren BR. et al. The effect of treating institution on outcomes in head and neck cancer. Otolaryngol Head Neck Surg 2012; 147: 1083-1092
• 7 Shaw RJ. Holsinger FC. Paleri V. et al. Surgical trials in head and neck oncology: Renaissance and revolution?. Head Neck 2015; 37: 927-930
• 8 Rosenthal DI. Mohamed AS. Weber RS. et al. Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. Cancer 2015; 121: 1608-1619
• 9 Wichmann G. Krüger A. Boehm A. et al. Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET/CT. Eur J Cancer 2017; 72: 144-155
• 10 Grégoire V. Langendijk JA. Nuyts S. Advances in Radiotherapy for Head and Neck Cancer. J Clin Oncol 2015; 33: 3277-3284
• 11 Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517: 576-582
• 12 Wichmann G. Rosolowski M. Krohn K. et al. The role of HPV RNA transcription, immune response- related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int J Cancer 2015; 137: 2846-2857
• 13 Kostareli E. Holzinger D. Bogatyrova O. et al. HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J Clin Invest 2013; 123: 2488-2501
• 14 Kostareli E. Hielscher T. Zucknick M. et al. Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients. Epigenetics 2016; 11: 61-73
• 15 Ferris RL. Blumenschein Jr G. Fayette J. et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375: 1856-1867
• 16 Chow LQ. Haddad R. Gupta S. et al. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol 2016; DOI: pii: JCO681478. Epub ahead of print